Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 8 - Number 3
The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
, 8(3): 172 - 179M. D. Bacolod, S. M. Lin, S. P. Johnson, N. S. Bullock, M. Colvin, D. D. Bigner and H. S. Friedman
DOI: 10.2174/156800908784293631
The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
, 8(3): 187 - 198Amancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, Wolfgang Link and Juan F.M. Leal
DOI: 10.2174/156800908784293659
Circulating Levels of VCAM and MMP-2 May Help Identify Patients with More Aggressive Prostate Cancer
, 8(3): 199 - 206Concetta De Cicco, Laura Ravasi, Laura Zorzino, Maria Teresa Sandri, Edoardo Botteri, Fabrizio Verweij, Donatella Granchi, Ottavio de Cobelli and Giovanni Paganelli
DOI: 10.2174/156800908784293613
Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
, 8(3): 207 - 222G. Del Poeta, A. Bruno, M. I. Del Principe, A. Venditti, L. Maurillo, F. Buccisano, R. Stasi, B. Neri, F. Luciano, A. Siniscalchi, P. de Fabritiis and S. Amadori
DOI: 10.2174/156800908784293640
Phosphorylation-Specific Prolyl Isomerase Pin1 as a new Diagnostic and Therapeutic Target for Cancer
, 8(3): 223 - 229Greg Finn and Kun Ping Lu
DOI: 10.2174/156800908784293622
Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice
, 8(3): 230 - 242Cristina Mastini, Pablo D. Becker, Manuela Iezzi, Claudia Curcio, Piero Musiani, Guido Forni, Federica Cavallo and Carlos A. Guzman
DOI: 10.2174/156800908784293604
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Advertisement
Webmaster Contact: info@benthamscience.net